{
  "docId": "019de070-182a-72ba-952e-2b048c610e12",
  "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 22,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a heatmap-style visualization to track individual patient progress across three mobility metrics (6MWT, GMFM-D, GMFM-E).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/10",
  "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12",
  "deckJsonHref": "/decks/019de070-182a-72ba-952e-2b048c610e12.json",
  "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.376,
        "x": 0.05,
        "y": 0.277
      },
      "kind": "callout",
      "text": "Overall clinical response rate: 56 Week Analysis: 11/13 (85%) 20 Week Analysis: 11/14 (79%)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ee27b1a-e88a-485d-9a10-c652f5e66276",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.45,
        "y": 0.17
      },
      "kind": "chart",
      "text": "Patient-level clinical response heatmap",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fddec17-c07d-446b-afbf-24f96c3f49b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.275,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "MCID for 6MWT = 9%; MCID for GMFM Part D is 2.4, 3.3, and 1.5 for GMFCS Levels I, II and III, respectively; MCID for GMFM Part E is 4.0, 2.8, and 1.8 for GMFCS Levels I, II and III, respectively. Maximum values for GMFM-D and GMFM-E are 39 and 72, respectively.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d218f4bf-4250-4935-b837-65b0f05dfb8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.46,
        "y": 0.82
      },
      "kind": "legend",
      "text": "Responder (≥1 MCID Increase); ≥-1 MCID decrease; No improvement or decline; Not assessed; Baseline deficit; No baseline deficit",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f424377e-172f-4208-88b2-89722ac1eb1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.376,
        "x": 0.05,
        "y": 0.64
      },
      "kind": "paragraph",
      "text": "Clinical Responder defined by achievement in one or more of three mobility assessments",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2dcd822-3763-4021-b819-976d61e50de6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Pegzilarginase Demonstrates Durable Clinical Response at 56 Week Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "daf5f26e-ed6f-4340-a45b-3f35a62a2486",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "heatmap-matrix",
      "slug": null,
      "matchId": "b0d6aa6c-6e18-4154-8217-48166c35271f",
      "evidence": "Patient-level clinical response data visualized as a color-coded grid.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "b75c20b9-aa91-43a1-bf22-7580f8be245b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Pegzilarginase Markedly Reduces and Sustainably Controls Plasma Arginine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "296138db-3606-465a-94b1-f4520a528394",
      "evidence": "Clear presentation of disease and treatment effects",
      "position": 0,
      "objective": "Understanding the problem and solution for Arginase 1 Deficiency",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}